Express Pharma
Home  »  Market  »  IPM clocks Rs 8349 crores in December 2015

IPM clocks Rs 8349 crores in December 2015


The market in Bihar grew the highest at 25 per cent followed by Punjab at 22 per cent

The Indian pharmaceutical market (IPM) has clocked Rs 8349 crores in December 2015 and has grown at 11.9 per cent. Amongst the top 10, Mankind grew by 18.1 per cent, Alkem by 18 per cent and Lupin at 15 per cent. 21 corporates have crossed the growth of IPM for the month of December 2015 amongst top 50. Amongst the top 50 corporate, Hetero had the highest growth of 33.3 per cent followed by Wockhardt at 29.7 per cent and Bharat Serums at 27.8 per cent. 28 corporates have shown growths of more than 10 per cent amongst the top 50.

Amongst the 11-20 ranked corporates, Alembic had the highest growth of 24 per cent followed by Micro at 20.4 per cent and Intas at 20.2 per cent. Amongst the 21-30 ranked corporates, Wockhardt has the highest growth at 29.7 per cent followed by Cadila at 22.2 per cent and FDC at 16.8 per cent. Amongst the 31-40 ranked corporates, Hetero grew at 33.3 per cent followed by Bharat Serums at 27.8 per cent and AstraZeneca at 14.5 per cent. Amongst the 41-50 ranked corporates, Troikaa had the highest growth at 16.8 per cent followed by Wallace at 15.4 per cent and Win-Medicare at 11.2 per cent.


Amongst the 51-60 ranked corporates, Boehringer grew at 60.6 per cent followed by Corona at 39.8 per cent and Centaur at 30.6 per cent. Amongst the 61-70 ranked corporates, Fresenius Kabi grew at 27 per cent followed by RPG which grew at 23.9 per cent and East India at 19.7 per cent. Amongst the 71-80 ranked corporates, Samarth grew at 35.3 per cent followed by Walter Bushnell at 21.5 per cent and Roche at 20.1 per cent. Amongst the 81 -90 ranked corporates, Galpha grew at 41.2 per cent followed by Med Manor, which grew at 35.6 per cent followed by Jagsonpal at 17.9 per cent.

Amongst the 91- 100 ranked corporates, Ozone grew at 47 per cent followed by Veritaz at 29.5 .per cent and Dey’s Medical at 28 per cent. The 100th biggest corporate is Gland Pharma and 150th biggest corporate is Claris in the IPM. Mercury entered the top 150 corporate as on MAT Dec 2015.

Indian companies have grown at 13.4 per cent versus 7.1 per cent for MNCs in December 2015. Amongst the top 50 in MNCs, AstraZeneca by 14.5 per cent followed by MSD at 11.5 per cent and Janssen at 8.8 per cent.


Under the non-NLEM category, Indian companies grew at 14.5 per cent whereas MNCs grew at 6.8 per cent. The NLEM containing molecules market grew at 7.5 per cent whereas the non-DPCO market grew by 12.7 per cent and Non-Sch Para 19 market at 2.9 per cent resulting in an overall growth of 11.9 per cent for December 2015.

NLEM and mon-NLEM category showed unit growth at 4.7 per cent and 3.8 per cent respectively. The non-Sch Para 19 market grew at 2.9 per cent from units perspective.

From therapy perspective, 10 therapies have outgrown the IPM growth. The respiratory market grew at 18.1 per cent, gastrointestinal market grew at 13.2 per cent, pain and analgesics market grew at 11.3 per cent whereas anti-infectives grew at 14.4 per cent. The anti-diabetics market grew at 15.1 per cent and cardiac at 9.4 per cent in chronic business. The derma market grew by 11.4 per cent and the urology market at 12.7 per cent. The cardiac market have crossed Rs 12k crores and the difference between cardiac and GI market now stands at Rs 746 crores.

From regional perspective, 15 regions have outgrown the IPM growth. The Bihar market grew the highest at 25 per cent followed by Punjab at 22 per cent and Jharkhand at 21.1 per cent. The Tamil Nadu market grew at 8.1 per cent and two regions had negative growth.

Amoxycillin + clavulanic acid market grew at 16.4 per cent and glimepiride + metformin market grew at 10.9 per cent.

The markets of paracetamol grew at 37.4 per cent, atorvastatin 3.7 per cent, probiotic microbes at 22.9 per cent, cefixime 10.8 per cent, pantoprazole 13.2 per cent, montelukast + levocetrizine at 13.9 per cent, glimepiride + metformin + pioglitazone at 14.5 per cent, Vitamin-D at 20.2 per cent, hydroquinone + mometasone + tretinoin at -9.1 per cent, voglibose + metformin + glimepiride at 30.9 per cent, rosuvastatin at 16.2 per cent, protein supplements at 5.2 per cent, azithromycin at 19.4 per cent, calcium carbonate + Vit D3 market at -1.8 per cent, paracetamol + phenylephrine + chlorpheniramine at 16.3 per cent.

Mixtard leads the pack with Rs 34 crores followed by Corex at Rs 30 crores, glycomet GP and augmentin at Rs 28 crores.

Few brands who have gained ranks include Meronem (+94), Unwanted Kit (+56), Rotarix (+52), Trajenta (+35), Spasmoproxyvon Plus, Januvia (+27), Betnovate C (+26), Vertin (+23), Azithral (+22), Panderm Plus (+21), Rantac, Telma H (+19), Ultracet, Gluconorm G, Jalra M (+18), Mucain (+17), Ascoril Plus (+16), Calpol, Budecort, Betnesol (+15), Orofer XT, Betnovate N (+14), Telma, Zifi, Rosuvas, Levipil (+13), Dolo (+12), Pan D, Eltroxin (+11), Galvusmet (+10), Pantop, Allegra (+9), Jalra (+5), Sinarest (+4) amongst top 100 brands. Few brands that have moved up ranks fastest into Top 300 vrands for the month of December 2015 are Havrix, Ocid, Anafortan, Vaxigrip, Grafeel. The 300th biggest brand is Bio D3 Plus from Macleods.

A total of 234 brands and 396 SKUs were launched in December 2015. The top new brands were Dacihep, Loftair, Vilamid and Osmopres. Two Teneligliptin brands were launched. They were Tenlimac and Teneza. Within the VMS category, Ultra CO-Q (Meyer), Nervijen NP (Jenburkt), BD and D3 (Delvin), Theloxin C (Sundyota) and Gemshell (Mankind) were launched followed by Riax & Riaxm XR launch in Saxagliptin market from DRL in the anti-diabetic category. In the respiratory segment, Albutamol Plus (Centaur), Macbery DX (Macleods), Derisal (Zydus), Viscodyne LS Plus (Wockhardt), Lesafe (Saffron) were launched. There were three launches in Carica Papaya market. They were Caripap, Minmin PB and Platimax. Ledihep was the biggest launch in Sofosbuvir + Ledipasvir Market and Dacihep in Daclatasvir market and by an MNC was Lobun in December 2015.

About PharmaTrac

PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.

Terminologies used

MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.

For more information, visit

Comments are closed.